{
  "metadata": {
    "case_id": 75,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T18:31:59.295499",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/75_NCT04456634.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/75_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.4
        ],
        [
          0.65,
          0.95
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "AL&RUX",
            "type": "EXPERIMENTAL",
            "description": "Oral administration of:\n\n• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)",
            "interventionNames": [
              "Drug: 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
            ]
          },
          "pred_item": {
            "label": "Artemether-lumefantrine plus ruxolitinib",
            "type": "EXPERIMENTAL",
            "description": "Participants received standard-dose artemether-lumefantrine for 3 days, with oral ruxolitinib 20 mg administered 2 hours after each artemether-lumefantrine dose.",
            "interventionNames": [
              "Artemether-lumefantrine",
              "Ruxolitinib"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "AL& Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "20 mg/120 mg artemether-lumefantrine (AL) + Placebo",
            "interventionNames": [
              "Other: 20 mg/120 mg artemether-lumefantrine (AL) + Placebo"
            ]
          },
          "pred_item": {
            "label": "Artemether-lumefantrine plus placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received standard-dose artemether-lumefantrine for 3 days, with oral placebo administered 2 hours after each artemether-lumefantrine dose.",
            "interventionNames": [
              "Artemether-lumefantrine",
              "Placebo tablet"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.78,
          0.9,
          0.3
        ],
        [
          0.86,
          0.2,
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)",
            "description": "Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).",
            "armGroupLabels": [
              "AL&RUX"
            ],
            "otherNames": [
              "Sentinel Group 1 a and 1 b"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Ruxolitinib",
            "description": "Ruxolitinib 20 mg (Jakavi, Incyte) administered orally 2 hours after each artemether-lumefantrine dose, twice daily for 3 days (total ruxolitinib dose 120 mg).",
            "armGroupLabels": [
              "Artemether-lumefantrine plus ruxolitinib"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "20 mg/120 mg artemether-lumefantrine (AL) + Placebo",
            "description": "Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).",
            "armGroupLabels": [
              "AL& Placebo"
            ],
            "otherNames": [
              "Sentinel Group 1 a and 1 b"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Artemether-lumefantrine",
            "description": "Fixed-dose artemether-lumefantrine (Riamet, Novartis). Four tablets of 20/120 mg (total 80/480 mg per dose) were administered orally with 250 ml of full-fat milk twice daily over three consecutive days from day 1 at t = 0, 8, 24, 36, 48, and 60 hours (total 24 tablets, 480/2,880 mg artemether-lumefantrine).",
            "armGroupLabels": [
              "Artemether-lumefantrine plus ruxolitinib",
              "Artemether-lumefantrine plus placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 4,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.92
        ],
        [
          0.62
        ],
        [
          0.6
        ],
        [
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participant With Treatment-Related Adverse Events as Assessed by CTCAE V4.03, All of Observed and Self-reported AEs Affected, by Treatment Regimen.",
            "description": "Incidence, severity and relationship of observed and self-reported adverse events (AEs) were reported during the study up to 28 days after AL+Rux and AL+Placebo administration in all participants by treatment regimens.",
            "timeFrame": "up to 28 days after AL+Rux and AL+placebo administration"
          },
          "pred_item": {
            "measure": "Safety and tolerability of artemether-lumefantrine plus ruxolitinib compared with artemether-lumefantrine plus placebo",
            "description": "Frequency, nature, and severity of adverse events and serious adverse events; abnormalities in vital signs, 12-lead ECG (including QTcF), hematology, clinical biochemistry, coagulation, urinalysis, and physical examination, assessed to determine safety and tolerability of the combination regimen.",
            "timeFrame": "From first dose on Day 1 through end-of-study visit on Day 29"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Changes of Systolic and Diastolic Blood Pressure",
            "description": "Safety signals, trends or significant differences in blood pressure between treatment groups were were reported during the study up to 28 days after AL+Rux and AL+Placebo administration in all participants by treatment regimens.",
            "timeFrame": "up to 28 days after AL+Rux and AL+placebo administration"
          },
          "pred_item": null
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With Changes in Heart Rate",
            "description": "Safety signals, trends or significant differences in heart rate ( beats / min)between treatment groups were were reported during the study up to 28 days after AL+Rux and AL+Placebo administration in all participants by treatment regimens.",
            "timeFrame": "up to 28 days after AL+Rux and AL+placebo administration"
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants With ECG Changes",
            "description": "Safety signals, trends or significant differences in QT, QTcB and QTcF, QRS between treatment groups were were reported during the study up to 28 days after AL+Rux and AL+Placebo administration in all participants by treatment regimens.",
            "timeFrame": "up to 28 days after AL+Rux and AL+placebo administration"
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.86,
          0.18,
          0.4,
          0.4
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "AUECt of pSTAT3 Inhibition",
            "description": "Area under the effect curve (AUECt) of pSTAT3 inhibition levels",
            "timeFrame": "up to 28 days after AL+Rux and AL+placebo administration"
          },
          "pred_item": {
            "measure": "Effect of artemether-lumefantrine plus ruxolitinib or placebo on pSTAT3 inhibition",
            "description": "Percent inhibition of IL-6–stimulated STAT3 phosphorylation in white blood cells (%pSTAT3 inhibition), including area under the pharmacodynamic effect versus time profile over the dosing interval on Day 1 (AUECT) and the pharmacokinetic/pharmacodynamic relationship between ruxolitinib plasma concentration and %pSTAT3 inhibition.",
            "timeFrame": "Baseline (pre-dose on Day 1) and multiple time points up to approximately 168 hours after first dose (Day 8)"
          }
        }
      ]
    }
  ]
}